BFA
CLVS

BlackRock Fund Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

BlackRock Fund Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$66.2M Buy
1,490,258
+167,744
+13% +$5.9M 0.01% 1494
2016
Q3 		$47.7M Buy
1,322,514
+47,980
+4% +$1.03M 0.01% 1610
2016
Q2 		$17.5M Buy
1,274,534
+75,613
+6% +$1.11M ﹤0.01% 2100
2016
Q1 		$23M Buy
1,198,921
+44,935
+4% +$951K 0.01% 1901
2015
Q4 		$40.4M Sell
1,153,986
-81,894
-7% -$5.28M 0.01% 1623
2015
Q3 		$114M Buy
1,235,880
+196,771
+19% +$17M 0.03% 807
2015
Q2 		$91.3M Sell
1,039,109
-27,131
-3% -$2.32M 0.02% 1069
2015
Q1 		$79.1M Buy
1,066,240
+26,579
+3% +$1.88M 0.02% 1189
2014
Q4 		$58.2M Buy
1,039,661
+80,670
+8% +$4.24M 0.01% 1358
2014
Q3 		$43.5M Buy
958,991
+899
+0.1% +$37.6K 0.01% 1444
2014
Q2 		$39.7M Buy
958,092
+95,785
+11% +$4.93M 0.01% 1554
2014
Q1 		$59.7M Buy
862,307
+32,653
+4% +$2.4M 0.02% 1285
2013
Q4 		$50M Buy
829,654
+89,308
+12% +$4.86M 0.02% 1395
2013
Q3 		$45M Buy
740,346
+183,389
+33% +$13M 0.02% 1420
2013
Q2 		$37.3M Buy
+556,957
New +$25M 0.01% 1441

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's CLVS Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Clovis Oncology, Inc. (CLVS) stake by 13% in Q4 2016, buying an estimated $5.9M and bringing the position to 1,490,258 shares worth $66.2M. The position accounts for 0.01% of the portfolio, ranked #1494.

BlackRock Fund Advisors first reported a position in CLVS in Q2 2013 and has held it in 15 quarters since. The position peaked at $114M in Q3 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

  • BlackRock Fund Advisors held 1,490,258 shares of Clovis Oncology, Inc. worth $66.2M as of Q4 2016.
  • BlackRock Fund Advisors bought 167,744 Clovis Oncology, Inc. shares in Q4 2016, an estimated $5.9M.
  • Clovis Oncology, Inc. made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1494 holding.
  • BlackRock Fund Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Clovis Oncology, Inc. position peaked at $114M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.